13.07
1.32%
0.17
Handel nachbörslich:
13.10
0.03
+0.23%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$12.90
Offen:
$12.64
24-Stunden-Volumen:
5.46M
Relative Volume:
1.56
Marktkapitalisierung:
$594.29M
Einnahmen:
$27.10M
Nettoeinkommen (Verlust:
$-24.31M
KGV:
-11.17
EPS:
-1.17
Netto-Cashflow:
$-33.33M
1W Leistung:
-1.43%
1M Leistung:
-30.92%
6M Leistung:
+174.58%
1J Leistung:
+199.77%
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Firmenname
Capricor Therapeutics Inc
Sektor
Branche
Telefon
(310) 358-3200
Adresse
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Vergleichen Sie CAPR mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
13.07 | 594.29M | 27.10M | -24.31M | -33.33M | -0.83 |
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-10-21 | Eingeleitet | Piper Sandler | Overweight |
2024-05-17 | Eingeleitet | Oppenheimer | Outperform |
2024-01-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
2022-10-26 | Eingeleitet | Ladenburg Thalmann | Buy |
2018-12-26 | Herabstufung | Maxim Group | Buy → Hold |
2018-01-26 | Bestätigt | H.C. Wainwright | Buy |
2017-09-15 | Bestätigt | H.C. Wainwright | Buy |
2017-02-13 | Fortgesetzt | Rodman & Renshaw | Buy |
2016-07-06 | Fortgesetzt | H.C. Wainwright | Buy |
2016-06-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten
(CAPR) Trading Advice - Stock Traders Daily
Capricor Therapeutics (CAPR) Stock Dips Amid Biotech Sector Decl - GuruFocus.com
Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Update - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Trading Down 5.3%Here's Why - MarketBeat
Capricor Therapeutics (CAPR) Stock Drops Amid Volatile Biotech Sector - GuruFocus.com
High Growth Tech Stocks To Watch In December 2024 - Simply Wall St
RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead - MarketWatch
Some Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shareholders Look For Exit As Shares Take 27% Pounding - Simply Wall St
(CAPR) Pivots Trading Plans and Risk Controls - Stock Traders Daily
250,204 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Purchased by Point72 Asset Management L.P. - MarketBeat
Deramiocel's Promise Brightens Capricor's Outlook, With Strings Attached (NASDAQ:CAPR) - Seeking Alpha
Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission - Seeking Alpha
Jones Trading keeps $40 target on Capricor Therapeutics By Investing.com - Investing.com UK
Piper Sandler maintains $35 target on Capricor shares By Investing.com - Investing.com Canada
Capricor Therapeutics (CAPR) Stock Surges Amid Positive Analyst Ratings - GuruFocus.com
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Capricor Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Capricor Therapeutics to Present at Major Healthcare Conferences in December | CAPR Stock News - StockTitan
Walmart Inc (WMT-N) QuotePress Release - The Globe and Mail
Capricor Therapeutics Inc (NASDAQ:CAPR) Receives $34.50 Average Price Target from Analysts - MarketBeat
Capricor Therapeutics (CAPR) Sees Stock Surge Amid Positive Anal - GuruFocus.com
Pork Cutout (KMG25) Quote - The Globe and Mail
Capricor Therapeutics Executes Collaboration Agreement and Exclusive License Option with Janssen Biotech - Marketscreener.com
Capricor wins key EU designations for the lead asset - MSN
Capricor stock on watch after key EU designations (CAPR:NASDAQ) - Seeking Alpha
Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency - The Manila Times
(CAPR) Proactive Strategies - Stock Traders Daily
Capricor Therapeutics shares rated Buy by Jones Trading, boosted by DMD-CM therapy - Investing.com Canada
What is HC Wainwright's Estimate for CAPR FY2024 Earnings? - MarketBeat
KBW Bank Index (BKX) QuotePress Release - The Globe and Mail
Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Down 14.6% in October - MarketBeat
Is Capricor Therapeutics (CAPR) the Best Multibagger Stock to Buy Heading into 2025? - Yahoo Finance
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2024 Earnings Call Transcript - Insider Monkey
Capricor Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Capricor Therapeutics Inc (CAPR) Quarterly 10-Q Report - Quartzy
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Earnings call: Capricor outlines deramiocel's path to market for DMD treatment - Investing.com Canada
Capricor Therapeutics (NASDAQ:CAPR) Trading 7.3% Higher on Analyst Upgrade - MarketBeat
Cantor Fitzgerald Issues Positive Forecast for Capricor Therapeutics (NASDAQ:CAPR) Stock Price - MarketBeat
Decoding 12 Analyst Evaluations For Capricor Therapeutics - Benzinga
Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates - MSN
Capricor Therapeutics Advances with Strategic Expansions - TipRanks
Capricor: Q3 Earnings Snapshot - San Antonio Express-News
Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Capricor Therapeutics earnings missed by $0.02, revenue fell short of estimates - Investing.com UK
Finanzdaten der Capricor Therapeutics Inc-Aktie (CAPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Capricor Therapeutics Inc-Aktie (CAPR) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Litvack Frank | Director |
Dec 03 '24 |
Option Exercise |
1.10 |
20,391 |
22,430 |
46,278 |
Nippon Shinyaku Co Ltd | 10% Owner |
Sep 20 '24 |
Buy |
5.36 |
2,798,507 |
14,999,998 |
7,090,351 |
Musket David B | Director |
Aug 07 '24 |
Option Exercise |
1.39 |
34,000 |
47,260 |
81,692 |
COLLIER EARL M JR | Director |
Apr 23 '24 |
Option Exercise |
1.39 |
30,000 |
41,700 |
56,856 |
Musket David B | Director |
Apr 23 '24 |
Option Exercise |
1.39 |
16,156 |
22,457 |
47,692 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):